Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
15 Aug 2024
Historique:
received: 22 04 2024
accepted: 26 07 2024
medline: 15 8 2024
pubmed: 15 8 2024
entrez: 15 8 2024
Statut: aheadofprint

Résumé

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by human sera is a strong correlate of protection against symptomatic and severe Coronavirus Disease 2019 (COVID-19). The emergence of antigenically distinct SARS-CoV-2 variants of concern (VOCs) and the relatively rapid waning of serum antibody titers, however, raises questions about the sustainability of serum protection. In addition to serum neutralization, other antibody functionalities and the memory B cell (MBC) response are suggested to help maintaining this protection. In this study, we investigate the breadth of spike (S) protein-specific serum antibodies that mediate effector functions by interacting with Fc-gamma receptor IIa (FcγRIIa) and FcγRIIIa, and of the receptor binding domain (RBD)-specific MBCs, following a primary SARS-CoV-2 infection with the D614G, Alpha, Beta, Gamma, Delta, Omicron BA.1 or BA.2 variant. Irrespectively of the variant causing the infection, the breadth of S protein-specific serum antibodies that interact with FcγRIIa and FcγRIIIa and the RBD-specific MBC responses exceeded the breadth of serum neutralization, although the Alpha-induced B cell response seemed more strain-specific. Between VOC groups, both quantitative and qualitative differences in the immune responses were observed, suggesting differences in immunogenicity. Overall, this study contributes to the understanding of protective humoral and B cell responses in the light of emerging antigenically distinct VOCs, and highlights the need to study the immune system beyond serum neutralization to gain a better understanding of the protection against emerging variants.

Identifiants

pubmed: 39146376
doi: 10.1371/journal.ppat.1012453
pii: PPATHOGENS-D-24-00822
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1012453

Informations de copyright

Copyright: © 2024 van der Straten et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Karlijn van der Straten (K)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

Denise Guerra (D)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

Gius Kerster (G)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

Mathieu Claireaux (M)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

Marloes Grobben (M)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

Angela I Schriek (AI)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

Anders Boyd (A)

Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Stichting HIV monitoring, Amsterdam, the Netherlands.

Jacqueline van Rijswijk (J)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

Khadija Tejjani (K)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

Dirk Eggink (D)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.
Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

Tim Beaumont (T)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

Steven W de Taeye (SW)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

Godelieve J de Bree (GJ)

Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.
Amsterdam UMC, location Academic Medical Center, Department of Internal Medicine, Amsterdam, The Netherlands.

Rogier W Sanders (RW)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America.

Marit J van Gils (MJ)

Amsterdam UMC, location Academic Medical Center, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands.

Classifications MeSH